Across TCGA pan-cancer cohorts, COPRS Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated COPRS data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher COPRS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated COPRS expression acts as an unfavorable survival marker.
SARC and LIHC are the cancer types where COPRS Mutation most reproducibly stratifies survival.